Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment

Abstract

Introduction

The occurrence of sequelae after chemotherapeutic treatment has recently attracted increasing interest, particularly given the higher life expectancy of those with a lived experience of cancer. The cognitive alterations described following cancer experience normally occur during pharmacological treatment of the disease, however, it can prevail long after the cessation of therapy. This phenomenon is known as chemotherapy-induced cognitive impairment (CICI), chemofog or chemobrain. Preclinical research has shown that chemotherapeutic agents such as oxaliplatin, paclitaxel, cyclophosphamide, methotrexate, 5-fluorouracil or doxorubicin can induce short- and long-term deleterious effects in working memory and fear and spatial learning in a wide variety of rodent models (Table 1). Moreover, neuroimaging studies have collected data from patients following chemotherapeutic regime supporting chemotherapy induced alterations on brain structure and plasticity. These studies showed the presence of cognitive alterations independently on the tumour location; suggesting that chronic chemotherapy treatment may induce alterations on cognitive functionality (Wefel and Schagen, 2012; Conroy et al., 2013; McDonald et al., 2013; Sleurs et al., 2016).

Despite the great number of antineoplastic drugs available in the market, only a few of them have been tested on preclinical and clinical studies of CICI, emphasizing the lack of clinical evaluation of cognition-related side effects. In addition, the majority of models investigating CICI have limited their attention on non-CNS cancer types (Wefel and Schagen, 2012), especially on breast cancer, biasing thus the investigation of CICI into one sex population and type of cancer disease.

Among the most common cognitive deficiencies reported, are those of short-term working and visuospatial memories, verbal ability, executive functions and attention span (Conroy et al., 2013; Du et al., 2013; McDonald et al., 2013; Sleurs et al., 2016). These deficiencies are difficult to detect since the cognitive levels observed in CICI patients are often placed at the lower end of the normal range of the population. In addition, the lack of approved tests for CICI diagnosis complicates medical evaluation (Horowitz et al., 2018; Nguyen and Ehrlich, 2020). Similar limitations are observed in the cognitive rehabilitation of CICI patients. The current, palliative, therapies available involves physical activity and cognitive-behavioural therapy (Kesler et al., 2013; Ferguson et al., 2014; Fernandes et al., 2019). Even though these therapies seem to improve the life quality of the patients, they require a lot of time, effort and economical aids. Therefore, the ongoing investigation of CICI leads the attention to develop new pharmacotherapies attending to the neurobiological alterations associated with this disease.

There are a great number of biological mechanisms that seem to be implicated in the cognitive deficits induced by chemotherapy agents, including: direct neurotoxic effects, impaired neurogenesis or increased death of nervous cells, white matter abnormalities, inflammatory responses, oxidative stress and even alterations in the levels of sex and stress hormones (Sleurs et al., 2016; El-Agamy et al., 2019; Mounier et al., 2020; Nguyen and Ehrlich, 2020).

The endogenous cannabinoid system (ECS) is a complex signalling system comprised of cannabinoid type 1 (CB₁) and cannabinoid type 2 (CB₂) receptors; endocannabinoid ligands: anandamide (AEA) and 2-arachidonoylglycerol (2-AG); and catabolizing enzymes: fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (Viveros et al., 2012; Kaur et al., 2016; Woodhams et al., 2017; Fraguas-Sánchez et al., 2018; Gorzkiewicz and Szemraj, 2018; Micale and Drago, 2018; Zou and Kumar, 2018). Other related biogenic lipids such as oleoylethanolamine (OEA) and palmitoylethanolamine (PEA) are also included within the ECS as endocannabinoid-related compounds (Di Marzo, 2018). Interestingly, pharmacological modulation of the ECS has been shown to reduce cancer-induced side effects such as nausea, vomiting (Taylor et al., 2020) and peripheral neuropathy (Lynch et al., 2014; Masocha, 2018; Blanton et al., 2019). Several studies in animal models have evaluated the role of the ECS in the modulation of cognitive functions (Schreiner and Dunn, 2012; Cohen and Weinstein, 2018) indicating for example the anxiolytic effects of low doses of cannabinoids. However, only few trials with cannabinoids have evaluated the mood state of cancer patients. ∆-9-tetrahydrocannabinol (THC) and nabilone have been proposed as alleviators for cancer-related psychological disorders, including depression and anxiety (Guzmán, 2003), however they need to be further evaluated though clinical trials. As a matter of fact, to the best of our knowledge no study has ever analysed the potential therapeutic value of cannabinoid drugs in CICI (Kleckner et al., 2019).

In this review we aim to describe the role of the ECS in two well-known CICI-associated processes: neuroinflammation and oxidative stress. In lack of specific studies on the topic, we will review the involvement of the ECS in cancer disease and other pathologies exhibiting similar cognitive phenotype to CICI.

Cannabinoids and Cancer

From a preclinical perspective, several studies have reported the involvement of the ECS in cancer disease. Increased expression of endocannabinoid receptors and ligand levels have been classically associated with carcinogenesis processes and a higher aggressiveness of cancer (Zhu et al., 2000; Hart et al., 2004; McKallip et al., 2005). Additionally, CB₂ receptors have been demonstrated to regulate HER2 (human epidermal growth factor receptor 2) oncogene expression, whose upregulation increases vulnerability to leukemia induced by viral infection (Pérez-Gómez et al., 2015).

Regarding the ECS as a therapeutic target against cancer activity, it has been observed its implication in the inhibition of cell proliferation and/or angiogenesis in different tumour types (Śledziński et al., 2020). Attending to cancer cell type and substance, the anti-tumorigenic effects of cannabinoids have been shown to be mediated via CB₁, CB₂ and TRPV1 receptors. Cell activation of CB₂ receptors led to a reduced cell motility in bladder cancer, decreasing proliferation rates (Bettiga et al., 2017). The phytocannabinoids THC and Cannabidiol (CBD) have been also reported to exert anti-tumour effects on U-87 MG cell-derived tumour xenografts by decreasing cancer growth via cell apoptosis (Torres et al., 2011). THC was shown to induce apoptosis of primary brain tumour cells (Carracedo et al., 2006) and to inhibit tumour growth and survival in a murine Lewis lung adenocarcinoma model (Ramer and Hinz, 2017). Interestingly, knockout mice for CB₁/CB₂ receptors exhibited a lower incidence to develop skin cancer after treatment with ultraviolet radioation (Surh et al., 2008). In vivo investigations have revealed cannabinoid-inhibition of tumour angiogenesis by inhibition of vascular endothelial cell migration and survival; as well as suppression of proangiogenic factor and matrix metalloprotease (MMP) expression in tumours (Blázquez e al., 2003). Cannabinoid administration has also been associated with a significant decrease in the expression of proangiogenic factors VEGF and Ang2, which result essential for the vascularization of different types of tumours (Carmeliet and Jain, 2000; Casanova et al., 2002). Altogether, the anti-tumour activity, including cancer cell death induction and angiogenesis inhibition, of cannabinoid drugs remark their potential as emergent and effective pharmacological targets in cancer.

Despite the potential anti tumorigenic effects demonstrated in numerous preclinical evaluations only one clinical study tested THC phytocannabinoid as systemically anticancer agent in glioblastoma multiforme (Guzmán et al., 2006). THC was injected intracranially into patients with an early diagnosed glioblastoma. However, the experiment failed to provide strong data supporting THC’s efficacy at that cancer stage. Recent clinical investigations have tested the administration of exocannabinoid compounds, such as Sativex, CBD or dexanabidiol, in different modalities of cancer (e.g. glioblastoma, advanced solid tumours, brain cancer, and neck squamous cell carcinoma); showing reductions in circulating tumour cells, reductions in tumour size, improved survival rate or reduced risk of head and neck squamous cell carcinoma (Moreno et al., 2019). Another possible approach could combine the use of chemotherapeutic agents and cannabinoid drugs to establish whether cannabinoids can enhance the current drug treatments. The few experiments that have investigated this hypothesis have shown controversial results. One study, using γ-radiation combined with a cannabinoid-based treatment demonstrated increased leukemic cell death than single administration of γ-radiation (Jacobsson et al., 2000). However, synergism was not observed when cannabinoids and tamoxifen were combined to induce glioma cell death (Radin, 2003).

It is important to remark that cannabinoids are currently used in palliative medicine for treatment of nausea and vomiting in cancer patients undergoing chemotherapy (Besner et al., 1992; Hall et al., 2001; Walsh et al., 2002). In addition, several preclinical studies have shown beneficial effects of cannabinoid drugs in chemotherapy-induced neuropathy, which is a common side effect of several chemotherapeutic agents, especially platinum-based compounds and taxanes (Abrams and Guzman, 2015; Blanton et al., 2019). Even though the anticancer effectiveness of cannabinoid drugs still remains unclear, its clinical use for the alleviation of cancer side effects such as pain, vomiting, nausea or anorexia is well stablished (Abrams and Guzman, 2015; Dariš et al., 2019; Vecera et al., 2020).

Taking this context into account, the following sections aim to clarify the involvement of the ECS in the two main processes underlying chemotherapy-induced cognitive impairment: neuroinflammation and oxidative stress.

Cannabinoids and Neuroinflammation

The presence of a tumour and/or the pharmacological management of cancer provokes the activation of the immune system. This mechanism of defence promotes the release of pro-inflammatory mediators responsible for an inflammatory response (Mounier et al., 2020). The pro-inflammatory factors reach the central nervous system (CNS) enhancing the inflammatory response through the activation of glial cells such as microglia and astroglia (Nguyen and Ehrlich, 2020) and promote the release of proinflammatory cytokines such as: tumour necrosis factor alpha (TNFα), interleukin 1 (IL-1) and interleukin 6 (IL-6). A persistent neuroinflammatory response provokes, among others, alterations in neurogenesis and changes in the myelination processes (Mounier et al., 2020), which are responsible for the emergence of cognitive impairments (Fourrier et al., 2019).

The ECS plays a key role in the homeostasis of the immune system. The ECS modulation of the immune system can promote neurogenesis or neurodegeneration (Molina-Holgado and Molina-Holgado, 2010; Tanasescu et al., 2013). Cannabinoid drugs have been used as therapeutic tools in a great number of neuroinflammatory and ageing animal models that involve cognitive dysregulation (Bisogno and di Marzo, 2008; Bilkei-Gorzo, 2012; Chiurchiù et al., 2018; Estrada and Contreras, 2020). As reported below, several studies have analysed the neuroprotective actions of cannabinoid drugs in pathologies that combine neuroinflammatory responses and cognitive impairments, but present different aetiologies, such as Parkinson’s disease (PD), Alzheimer’s disease (AD) or traumatic brain injury (TBI) (Schurman and Lichtman, 2017; Rodrigues et al., 2019; Uddin et al., 2020). In this section, we propose to analyse the modulatory effect of cannabinoids in these neuropathologies to envision the potential beneficial role over CICI.

PD is a progressive and chronic neurodegenerative disorder characterized by the death of dopaminergic neurons in the substantia nigra pars compacta and the presence of intraneuronal inclusions of the protein a-synuclein, generally known as Lewy bodies (Braak et al., 2004; Concannon et al., 2015a; Rodrigues et al., 2019). In PD patients and animal models of PD, the ECS is highly dysregulated (Concannon et al., 2015a; Concannon et al., 2015b), suggesting an implication of this system in the pathology and progression of the disease. In addition, it has also been observed that pharmacological modulation of the ECS can induce neuroprotective actions in PD (Aymerich et al., 2018). For instance, the CB₁ receptor agonist HU-210 exhibited neuroprotective properties to 6-hydroxydopamine (6-OHDA) neurotoxicity in vitro. This neuroprotective effect was greater in the presence of glial cells, suggesting that HU-210 neuroprotection depends on its ability to modify this type of cells (Lastres-Becker et al., 2005). Similar results were observed in two animal models of PD-induced neuroinflammation; PD induced by lipopolysaccharide (LPS) and PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Both animal models exhibited a reduction of microglial activation, thus pro-inflammatory cytokines expression, following HU-210 and WIN55,212-2, CB1 and CB1/CB2 agonists respectively, administration (Chung et al., 2011; Chung et al., 2012). In addition to WIN55,212–2, the CB₂ receptor agonist JWH155 induced a similar effect against MPTP neurotoxicity, while CB₂ receptor genetic ablation exacerbated MPTP neurotoxicity (Price et al., 2009). Likewise, CB₂ receptor knockout mice are more sensitive to the neuroinflammatory effects induced by LPS compared to their wild littermates (García et al., 2011). Additionally, an increase in CB₂ receptor expression has been positively correlated with an increase of microglial activation (Concannon et al., 2015b) in animal models of neuroinflammation and neutoxocity. Moreover, recent post-mortem studies have shown that there is an increase in the expression of CB₂ receptors in microglia of the substantia nigra and a decreased expression of this cannabinoid receptor in tyrosine hydroxylase-positive cells in patients suffering from PD (García et al., 2015; Gómez-Gálvez et al., 2016). Additionally, it was detected, in neurotoxic and inflammation-driven animal models of PD, an increase in CB₂ receptor expression that correlated with an increase of microglial activation (Concannon et al., 2015b), attributing clinical relevance to the involvement of CB₂ receptors in neuroinflammatory processes associated with PD.

AD is a neuropsychiatric and neurodegenerative disorder with an important neuroinflammatory component. In fact, chronic inflammation contributes to the pathophysiology of AD and is closely associated to the neuropathological and cognitive syndromes of AD (Marchalant et al., 2008; Bonnet and Marchalant, 2015). Several studies have observed that the activation of CB₂ receptors decrease neuroinflammation in animal models of AD (Uddin et al., 2020). In a recent study the administration of the CB₂ receptor agonist JWH-015 induced a significant reduction of the gene expression of pro-inflammatory cytokines in the prefrontal cortex of the APP/PS1 double transgenic mice linked to a decrease of the microglial biomarker Iba-1. Yet, CB₂ activation did not reduce neuroinflammation in the hippocampus or decreased the β-amyloid plaque deposition (Li et al., 2019). In addition, administration of JWH-015 in these transgenic mice improved their working memory in the novel object recognition test, but not their spatial memory measured in the Morris water maze (Li et al., 2019). In the same animal model, the administration of the CB₁ receptor agonist ACEA decreased astroglial response in the vicinity of β-amyloid plaques and decreased the expression of the pro-inflammatory cytokine interferon-γ in astrocytes (Aso et al., 2012). ACEA also improved the working memory and decreased the activity of Akt and ERK in the hippocampus of another AD animal model consisting in intracerebroventricular administration of streptozotocin (STZ) (Crunfli et al., 2019). CBD is one of the main pharmacologically active phytocannabinoids of the plant Cannabis sativa L. (Atalay et al., 2020), but, unlike THC, it does not produce psychotropic effects and presents no affinity to CB₁ and CB₂ receptors. In vitro studies have described the anti-inflammatory effects of CBD (Esposito et al., 2006a; Esposito et al., 2006b; Martín-Moreno et al., 2011), however, recent in vivo studies have failed to relate these effects with a reversion of cognitive impairments in animal models of AD (Cheng et al., 2014a; Cheng et al., 2014b; Watt et al., 2020) which may indicate that CB₁ and CB₂ receptors play a crucial role in the cognitive impairments induced by the inflammatory response and they are potential therapeutic targets to take into account in future experiments.

Traumatic Brain injury (TBI) is a non-degenerative disease induced by a mechanical neuronal damage. This type of damage triggers a cascade of neuroinflammatory events usually followed by an increase of endocannabinoid ligand levels: AEA and 2-AG. This effect is thought to be an immediate response to maintain brain-related homeostasis since binding of these ligands to CB₁ and CB₂ receptors generate an anti-inflammatory response in an attempt to counteract the injury-related inflammation (Vázquez et al., 2015; Schurman and Lichtman, 2017). AEA levels have been shown to be increased in the brain ipsilateral side of the lesion in different TBI animal models, a compensatory effect that is thought to prevent cell degeneration. Administration of the FAAH inhibitor PF-3845 prevented dendritic loss and restored the levels of synaptophysin, a synaptic transmission precursor, in the ipsilateral dentate gyrus. Furthermore, the administration of PF-3845 (5 mg/kg) reversed TBI-induced impairment of hippocampal-dependent memory. However, since PF3845 not only induced an increase on AEA levels but also 2-AG levels (Tchantchou et al., 2014), both endocannabinoid ligands could be involved in this neuroprotective activity observed in the ipsilateral brain. In addition, CB₁ receptor antagonists reverted 2-AG anti-inflammatory effects suggesting 2-AG-mediated activation of CB₁ receptors induce neuroprotection (Panikashvili et al., 2001; Panikashvili et al., 2005; Panikashvili et al., 2006). TBI also induces a significant increase of CB₂ receptors expression in the injured cortex. Activation of CB₂ receptors by GP1a (a CB₂ receptor agonist) induced a significant decrease in the levels of pro-inflammatory cytokines as well as an increase in the number of M2 macrophages in a TBI animal model (Braun et al., 2018). Since CB₁ and CB₂ activation plays such an important role counteracting the neuroinflammatory response after TBI it is not surprising that two well-known neuroprotective compounds with no direct relation with the ECS, such as the antibiotic minocycline and the hormone leptin, had their anti-inflammatory properties blocked when CB₁ and CB₂ receptor antagonists were administered (Lopez-Rodriguez et al., 2015; Lopez-Rodriguez et al., 2016). Although the use of cannabinoid drugs following TBI has been linked to decreased inflammatory cell activation and decreases in pro-inflammatory cytokine production (Price et al., 2009), little is known about the prevention or reversion of the development of cognitive impairments after TBI.

Cannabinoids and Oxidative Stress

Chemotherapeutic drugs induce an increase of the mitochondrial production and accumulation of reactive oxygen and nitrogen species (ROS/RNS), a phenomenon known as oxidative stress (Lipina and Hundal, 2016; Atalay et al., 2020; Mounier et al., 2020). Intracellular accumulation of ROS and RNS results in cell damage and subsequent death (Lipina and Hundal, 2016; Umeno et al., 2017; Gallelli et al., 2018; Atalay et al., 2020). Oxidative stress is especially toxic in cancer cells due to their high metabolic rate, however, healthy cells in the CNS can also be damaged by the oxidative stress-related toxicity generated by chemotherapeutic agents (Kawai et al., 2006; Rajamani et al., 2006; Joshi et al., 2007; Tangpong et al., 2007; Liu et al., 2009).

In the past few years, it has been observed a correlation between the ECS and the synthesis of ROS/RNS. For instance, the ECS has been demonstrated to modulate the activity and expression of key enzymes involved in the synthesis of oxygen reactive species in the CNS, such as NOX2 and NOX4 (Lipina and Hundal, 2016; Gallelli et al., 2018). Moreover, AEA is able to partially reverse oxidative stress induced by exposure to hydrogen peroxide in a culture of hippocampal neural HT22 cells. In particular, AEA increased the cellular metabolic rate and decreased the number of apoptotic cells. AEA also increased the expression of the antioxidant enzyme superoxide dismutase (SOD) and decreased mRNA expression of NOX2 provoking a significant reduction of the intracellular levels of ROS. These AEA-related antioxidant effects were attributed to the activation of CB₁ receptors, since their pharmacological and genetic blockade reversed those effects (Jia et al., 2014). The ECS can also regulate oxidative stress and lipid peroxidation by conveying beneficial free radical scavenging effects or through directly targeting CB₁ and CB₂ receptors (Lipina and Hundal, 2016; Gallelli et al., 2018). Interestingly, the beneficial or detrimental effects induced by the activation of cannabinoid receptors on ROS/RNS synthesis, seems to depend on the cell type and the aetiology and stage of the disease, and CB₁ and CB₂ receptors seem to have opposite effects in ROS formation. In the murine macrophage cell line RAW264.7, CB₁ receptor activation promoted ROS formation via phosphorylation of p38-mitogen-activated protein kinase, whereas CB₂ receptors suppressed this CB₁ receptor-mediated effect (Han et al., 2009). Interestingly, this opposite action of CB₁ and CB₂ receptors has been documented in studies in which the oxidative stress was caused by a chemotherapeutic agent. For instance, acute and chronic administration of doxorubicin increased markers of oxidative/nitrosative stress in the myocardium of CB₁ ^+/+ mice. This effect was attenuated in CB₁ ^−/− mice, suggesting the implication of CB₁ receptors in the oxidative stress induced by doxorubicin (Mukhopadhyay et al., 2010a). In addition, CB₁ receptor agonists, such as AEA and HU-210, increased ROS generation in human cardiomyocytes, and this effect was attenuated by the concomitant application of the CB₁ receptor antagonists SR1 and AM281 (Mukhopadhyay et al., 2010b). Similarly, cisplatin administration induced a significant increased expression of renal ROS/RNS synthesising enzymes, such as NOX2 and NOX4, and cell death. These deleterious effects were attenuated by the blockade of CB₁ receptor or activation of CB₂ receptors thus protecting against tubular damage (Mukhopadhyay et al., 2010a; Mukhopadhyay et al., 2010c; Horváth et al., 2012).

There is a great number of neuropathologies that cause an increment of the oxidative stress, including neurodegenerative diseases that are commonly associated with the development of cognitive deficits such as AD and PD. In fact, the antioxidant properties of cannabinoid drugs and their effect on cognition have been extensively studied in neurodegenerative animal models. In the STZ animal model of AD, a chronic treatment with the CB₁ receptor agonist ACEA induced a reduction of nitric oxide (NO) accompanied by an improvement of the short- and long-term working memory measured by novel object recognition test (Crunfli et al., 2019). In a neurotoxic animal model of AD, the injection of β-amyloid peptide in the frontal cortex induced an important neural loss in the CA1, CA2 and CA3 hippocampal regions accompanied with the increased expression of biomarkers for apoptosis and gliosis, only 12 days following β-amyloid peptide administration. It was also observed an increase of the pro-oxidative enzyme inducible nitric oxide synthase (iNOS). Acute administration of VDM11, an inhibitor of AEA cellular reuptake, ameliorated the amnesia induced by β-amyloid peptide administration in the passive avoidance task. Interestingly, the significant increase in the hippocampal levels of AEA induced by the repeated administration of VDM11 reduced the neuronal loss and also the expression of iNOS (van der Stelt et al., 2006). A similar effect was observed when CB₁ receptors were pharmacologically activated by administration of HU-210 or WIN55,212–2 in the MPTP-induced animal model of PD. Treated animals showed enhanced survival of nigrostriatal dopaminergic neurons, suppressed NOX enzymes and decreased ROS production (Chung et al., 2011).

Other cannabinoid-related compounds have recently attracted attention for their neuroprotective and antioxidant properties. One of these compounds is the endogenous lipid mediator PEA. In the 3xTg genetic mouse model, which contains three well established mutations for the development of AD, a chronic treatment for 90 days with ultramicronized PEA resulted in the rescue of the memory deficits typically observed in this phenotype of mice (Scuderi et al., 2018). Interestingly, this treatment also reversed astrogliosis and neuroinflammation, incremented the expression levels of BDNF in the hippocampus and decreased iNOS levels (Bronzuoli et al., 2018). Another different cannabinoid compound that has been extensively studied for its antioxidant properties is CBD. CBD, like other antioxidants, can modify the level and activity of oxidants and antioxidants and interrupt free radical chain reactions (Atalay et al., 2020). CBD administration also reduces the oxidant effects of chemotherapy drugs. For instance, CBD reduced iNOS levels in cardiac tissue and decreased serum levels of NO in mice treated with doxorubicin (Fouad et al., 2013). In addition, in the mouse model of cisplatin-induced nephropathy, CBD markedly attenuated cisplatin-induced oxidative/nitrosative stress, inflammation and cell death, improving renal function (Pan et al., 2009). As previously mentioned, these CBD antioxidant effects are similar to that provoked by the blockade of CB₁ or the activation of CB₂ receptors in this same animal model of nephropathy (Mukhopadhyay et al., 2010a; Mukhopadhyay et al., 2010c; Horváth et al., 2012). In the neurotoxic animal model of AD induced by the intracerebroventricular administration of β-amyloid peptide in mice, chronic administration of CBD reduced the hippocampal expression of iNOS and the subsequent NO release (Esposito et al., 2007) and prevented the spatial memory deficits usually observed in this animal model (Martín-Moreno et al., 2011). CBD was also able to recover 6-OHDA-induced dopamine depletion in this animal model of PD, but only when it was administered immediately after the lesion. This effect was accompanied by an increase in the levels of SOD (García-Arencibia et al., 2006).

Clinical evidence for the use of cannabinoid drugs in cognitive-related diseases

The preclinical findings on the antioxidant and anti-inflamatory effects induced by the pharmacological modulation of the ECS during PD or AD has also been translated into the clinical field. Despite the vast evidence of cannabinoids-induced neuroprotection in TBI, there are still no studies translating those finding into humans. Elevated endocannabinoid levels have been found in the cerebrospinal fluid of PD patients, together with decreased CB₁ receptors in the basal ganglia (Hurley et al., 2003; Pisani et al., 2005). A small human trial performed in patients suffering from PD revealed that cannabinoid-related drugs such as CBD, nabilone or even cannabis improved motor symptoms an attenuated levodopa-induced dyskinesia. Moreover, resting tremor, rigidity, bradykinesia, and posture were corrected, followed by a decrease on pain sensitivity and amelioriated sleep quality (Carroll et al., 2004; Mesnage et al., 2004; Lotan et al., 2014). CBD has also been associated with diminished REM sleep behavior disorder in PD patiens (Chagas et al., 2014).

A post-mortem study in human brain samples of AD patients showed an increased expression of CB₂ receptors in microglia associated with β-amyloid-enriched neuritic plaques. This effect was not detected in CB1 receptors expression, suggesting the involvement of CB₂ dependent mechanisms in this disorder (Benito et al., 2003). Several clincial studies have investigated the effects of dronabinol, which is a synthetic version of THC, in advanced stages of AD. Dronabinol improved side effects associated with late stages of AD such as food intake, sleep duration and circadian rhythm; decreasing also agitation (Volicer et al., 1997; Woodward et al., 2014; Suryadevara et al., 2017).

These reports demonstrate the potential therapeutic activity of cannabinoid drugs to relieve PD and AD symthomatology. However, to the best of our knowledge, there is no clinical evidence of improvement in the cognitive alterations associated with these neurodegenerative disorders yet. Further clinical and preclinical research is required to assess the cognitive-related therapeutic effects that cannabinoid drugs may exert.

Discussion

Due to the increased survival of cancer patients, there is an urgent need to address the possible sequelae that the current treatments may provoke. Amongst these adverse effects, those affecting cognition and other brain functionality are particularly worrying. The occurrence of chemotherapy-induced cognitive impairment (CICI) has been demonstrated in animal models and human patients. Different biological mechanisms seem to be involved, however there is a big gap in the understanding of those yet. The ECS is implicated in neuroinflammation and oxidative stress (Figure 1). This review comprehends evidence on the use of cannabinoid-related drugs for the modulation of neuroinflammation and oxidative stress in different pathologies with similar cognitive phenotype to CICI, as well as their anti-tumour activity.

The data collected elucidate the positive outcomes of cannabinoid-based drugs in the relief of PD- and AD-side effects in human patients. These results highlight the possible therapeutic potential of cannabinoid drugs in the treatment of CICI. The lack of clinical evidence supporting the anti-cancer role described of the ECS in animal and in vitro models, emphasizes the importance of translating the preclinical findings into humans. This fact points forward the urgent need of clinical assays where the preclinical effectiveness of cannabinoid drugs in the recovery of chemotherapy-induced cognitive alterations can be also investigated.

References